Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Duodenum harbors a Broad Untapped Therapeutic Potential.
van Baar ACG, Nieuwdorp M, Holleman F, Soeters MR, Groen AK, Bergman JJGHM. van Baar ACG, et al. Gastroenterology. 2018 Mar;154(4):773-777. doi: 10.1053/j.gastro.2018.02.010. Epub 2018 Feb 8. Gastroenterology. 2018. PMID: 29428335 No abstract available.
Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes mellitus: one year results from the first international, open-label, prospective, multicentre study.
van Baar ACG, Holleman F, Crenier L, Haidry R, Magee C, Hopkins D, Rodriguez Grunert L, Galvao Neto M, Vignolo P, Hayee B, Mertens A, Bisschops R, Tijssen J, Nieuwdorp M, Guidone C, Costamagna G, Devière J, Bergman JJGHM. van Baar ACG, et al. Gut. 2020 Feb;69(2):295-303. doi: 10.1136/gutjnl-2019-318349. Epub 2019 Jul 22. Gut. 2020. PMID: 31331994 Free PMC article. Clinical Trial.
Duodenal mucosal resurfacing combined with glucagon-like peptide-1 receptor agonism to discontinue insulin in type 2 diabetes: a feasibility study.
van Baar ACG, Meiring S, Smeele P, Vriend T, Holleman F, Barlag M, Mostafavi N, Tijssen JGP, Soeters MR, Nieuwdorp M, Bergman JJGHM. van Baar ACG, et al. Gastrointest Endosc. 2021 Jul;94(1):111-120.e3. doi: 10.1016/j.gie.2020.12.021. Epub 2020 Dec 24. Gastrointest Endosc. 2021. PMID: 33359437 Free article. Clinical Trial.
Safety and efficacy of hydrothermal duodenal mucosal resurfacing in patients with type 2 diabetes: the randomised, double-blind, sham-controlled, multicentre REVITA-2 feasibility trial.
Mingrone G, van Baar AC, Devière J, Hopkins D, Moura E, Cercato C, Rajagopalan H, Lopez-Talavera JC, White K, Bhambhani V, Costamagna G, Haidry R, Grecco E, Galvao Neto M, Aithal G, Repici A, Hayee B, Haji A, Morris AJ, Bisschops R, Chouhan MD, Sakai NS, Bhatt DL, Sanyal AJ, Bergman JJGHM; Investigators of the REVITA-2 Study. Mingrone G, et al. Gut. 2022 Feb;71(2):254-264. doi: 10.1136/gutjnl-2020-323608. Epub 2021 Feb 17. Gut. 2022. PMID: 33597157 Free PMC article. Clinical Trial.
Duodenal mucosal resurfacing with a GLP-1 receptor agonist increases postprandial unconjugated bile acids in patients with insulin-dependent type 2 diabetes.
Meiring S, Meessen ECE, van Baar ACG, Holleman F, Nieuwdorp M, Olde Damink SW, Schaap FG, Vaz FM, Groen AK, Soeters MR, Bergman JJGHM. Meiring S, et al. Among authors: van baar acg. Am J Physiol Endocrinol Metab. 2022 Feb 1;322(2):E132-E140. doi: 10.1152/ajpendo.00337.2021. Epub 2021 Dec 27. Am J Physiol Endocrinol Metab. 2022. PMID: 34957857 Free PMC article.
19 results